Grateful for @JWatch for the opportunity! I thoroughly enjoyed writing this piece and hope we can continue this conversation about #IMG. #MedTwitter#residency
Dr. Khalid A. Shalaby shares what it's like to be an IMG, or an International Medical Graduate, including going through the visa process during the pandemic. Check out the latest Insights on Residency Training post: https://t.co/zwN84dAqWv #MedTwitter@ShalabyK
HIGHEST RANKED TRIALS for 2025
TOP 10 #cancerclinicaltrials in 2025 w/MOST Impact
1/ #DeLLphi304@NEJM led by #Zeusofoncology@g_mountzios@HenryDunantGR : In relapsed SCLC post-platinum, BiTE DLL-3 Tarlatamab improved mOS vs. Chemo (13.6 vs 8.3 m, HR 0.60). PFS and in cancer-related dyspnea also improved.
https://t.co/dlIvlySUT9
being a #chiefresident is truly the weirdest job in the world, but with just over one week left, I’ve been really reflecting on what a growth experience this has been both personally and professionally.
here are 12 things I learned (other than how to be a much better educator):
@Salma6491 الواحد كل ما يفتكر إنه مبتلى يبص حواليه نص دقيقة يعرف إن نعم ربنا لا تحصى. ربنا يرحمها و يصبرهم و يجمعهم في الجنة. الحمد لله. و إنا لله و إنا إليه راجعون.
A few reasons why I’ve been late to see patients:
A child’s cancer relapsed, family devastated
An adolescent expressed suicidal intent
A child with life threatening anaphylaxis
Things that have never been the reason I was late:
Eating bon bons
Not valuing patients time
📢 We are thrilled to announce that the 2nd edition of the #EBMT Handbook has been released, addressing the most recent developments and innovations in #HCT and #CellularTherapy 📖
Find out more and download your copy here ⬇️
https://t.co/hTK7z8i7Zp
#mmsm@FDAOncology discussion on MRD as a surrogate endpoint for accelerated approvals in myeloma
On trial level, associations are weak-moderate overall
On individual level, strong association
This means: MRD is prognostic though not ready yet to be a surrogate for approval👇
Roswell Park is an authorized treatment center for the newly FDA-approved TIL therapy, Amtagvi, for use in patients with metastatic melanoma whose disease has not responded to other therapies.
Amtagvi, is the first FDA-approved therapy of its kind for solid tumor cancers.
@JamshedNamirah https://t.co/62KJUVSCe4
Wrote about it a while ago. If anyone can imagine, it has gotten exponentially worse since then. Happy to collaborate on a petition for change.